Drug facts

Microdosing

Reviewed August 2026

What people mean by the word¹

The term comes from patients and prescribers, not from a regulator. Cleveland Clinic describes microdosing a GLP-1 as when you intentionally take a reduced amount of the medication, and gives two reasons people do it: to make a supply last longer and therefore cost less, and out of concern about regaining weight after stopping. The same piece is direct about the evidence — there’s a lack of research on the safety of microdosing these weight loss drugs and any benefits to your health — and notes that there is not enough research to understand the effectiveness or safety of microdosing compounded GLP-1s.

The cost motive is real and worth taking seriously on its own terms. It is also the one part of this that can be settled with arithmetic rather than speculation: what a given seller actually bills over a month, at the dose you are actually on, is what our true monthly cost calculator exists to work out.

The word is not in the label²

We searched the complete published prescribing information — not a summary of it, the full text, roughly 200,000 characters — for microdose and microdosing. Neither string appears. That is not a criticism of the practice; it is a statement about where the practice stands relative to the document that governs the approved product. There is no labeled regimen to point to, so there is also no labeled evidence, no labeled titration and no labeled safety profile for it.

No dose below 2.5 mg is an approved starting dose³

Section 2.1 states that the recommended starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks, and that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. The escalation described from there moves in 2.5 mg increments after at least 4 weeks on the current dose. There is no lower rung on that ladder. The whole schedule, including the maintenance doses and the maximum, is laid out in the approved dosing schedule and its four-week steps.

What the trials actually tested⁴

Study 1 randomized 2,539 adults to a once-weekly fixed dosage of 5 mg, 10 mg, 15 mg or placebo, with an escalation period of up to 20 weeks followed by a maintenance period, and assessed weight reduction at 72 weeks. Study 2 randomized 938 adults with type 2 diabetes to 10 mg, 15 mg or placebo on the same design.

Read those arms against the question. The efficacy the approved product claims was measured at 5 mg and above, held for at least 52 weeks at a maintenance dose. No arm of either trial tested a dose below 2.5 mg, so there is no result to extrapolate down from — not a negative result, an absent one.

Why this is sharper for a compounded vial³

A compounded vial has no approved schedule of its own to depart from, and its concentration is set by the pharmacy rather than standardized, so the same fraction of a vial can mean different amounts of drug from different sellers. What is and is not established about compounded preparations generally is set out in what actually differs between a compounded vial and Zepbound, and what the drug does at any dose is covered in how tirzepatide acts on GIP and GLP-1 receptors.